GlassScriptPhysician profile
Carol A Beals
NPI 1992870166
$4,620.02
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,672 · 2020: $1,737 · 2022: $83.80 · 2023: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $126.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $717.64 | 2019-2023 | Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $664.58 | 2019-2022 | |
| Amgen INC. | $639.99 | 2019-2020 | |
| Abbvie INC. | $540.40 | 2019-2020 | |
| Pfizer INC. | $381.91 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $347.24 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $230.96 | 2019 | |
| Genentech USA, INC. | $129.77 | 2019-2020 | |
| Horizon Therapeutics Plc | $119.45 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $118.42 | 2019 | |
| Radius Health, INC. | $118.24 | 2019-2020 | |
| Ucb, INC. | $116.43 | 2019-2020 | |
| Glaxosmithkline, LLC. | $105.14 | 2019 | |
| Janssen Scientific Affairs, LLC | $98.16 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.58 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $54.06 | 2020 | |
| Lilly USA, LLC | $42.73 | 2019-2020 | |
| Genzyme Corporation | $35.81 | 2020 | |
| Orthogenrx INC. | $21.62 | 2019 | |
| Celgene Corporation | $19.38 | 2019 | |
| Mallinckrodt Hospital Products INC. | $19.08 | 2020 | |
| Strongbridge US INC. | $16.93 | 2020 | |
| Eisai INC. | $13.50 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Beals listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.